Cancer combo drug trial for rare skin cancer withdrawn before starting
NCT ID NCT05846724
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study planned to test a combination of two drugs, pembrolizumab and lenvatinib, in people with a rare skin cancer called classic Kaposi sarcoma that had not responded to prior chemotherapy. The goal was to see if the combination could shrink tumors better than standard chemotherapy. However, the trial was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSIC KAPOSI SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail targets rare, aggressive cancer
- Kaposi's sarcoma drug trial halted early – what we know
- Scientists seek tissue samples to unlock HIV-Cancer mysteries
- New drug shows promise in blocking kaposi sarcoma growth
- Can a smaller dose of this cancer drug still work? new trial aims to find out
- New hope for rare cancers: immunotherapy drug targets tumors regardless of origin